Shrinking the gHAT map: identifying target regions for enhanced control of *gambiense* human African trypanosomiasis in the Democratic Republic of Congo

Ching-I Huang^{a,b,*}, Ronald E Crump^{a,b,c,*}, Paul Brown^{a,b}, Simon E F Spencer^{a,d}, Erick Mwamba Miaka^e, Chansy Shampa^e, Matt J Keeling^{a,b,c}, Kat S Rock^{a,b}

^aZeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, U.K.

^bMathematics Institute, The University of Warwick, Coventry, U.K.

^c The School of Life Sciences, The University of Warwick, Coventry, U.K.

^d The Department of Statistics, The University of Warwick, Coventry, U.K.

^eProgramme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, D.R.C.

Abstract

Background

Gambiense human African trypanosomiasis (gHAT) is a disease targeted for elimination of transmission (EOT) by 2030, however the likelihood of achieving it is unknown. We utilised modelling to study the impact of currentlyavailable intervention methods on transmission across the Democratic Republic of Congo (DRC) – which accounts for $\sim 70\%$ of global burden – and highlight regions requiring intensified interventions.

Methods

A model previously fitted to case data in DRC was used to predict cases and new infections under four future strategies in 168 health zones. The strategies comprise of medical interventions – active and passive screening (AS and PS)

Preprint submitted to The Lancet Global Health

July 3, 2020

^{*}These authors contributed equally to this work.

Email address: ching-i.huang@warwick.ac.uk (Ching-I Huang)

– and some include large-scale vector control (VC). In each health zone, we estimate the median year of EOT and the probability of EOT by 2030 under each and compute the least ambitious strategy predicted to achieve EOT by 2030.

Findings

The model predicts 42 health zones are very likely to achieve EOT (> 90% probability) using medical-only strategies continued at mean coverage levels; this increases to 52 when AS coverage is increased to maximum previous coverage. In all VC strategies, health zones are predicted to meet EOT by 2030, although there are several where increasing low AS coverage could achieve this.

Interpretation

This analysis provides a priority list for consideration for supplementary VC implementation (Bagata, Bandundu, Bolobo, Kikongo, Kwamouth and Masi Manimba in former Bandundu province) in conjunction with the recent AS coverage.

Funding

Bill Melinda Gates Foundation [OPP1177824, OPP1184344, OPP1156227, OPP1186851, and OPP1155293] and Belgian Development Agency (EN-ABEL).

Keywords: gambiense human African trypanosomiasis, modelling, 2030 goals, elimination of transmission, Democratic Republic of Congo

Research in context

Evidence before this study

On 30th April 2020 we searched PubMed and ScienceDirect to identify previous predictive modelling studies of gHAT in DRC using the search terms "model" AND "Democratic Republic of Congo" OR "DRC" AND "trypanosomiasis" OR "sleeping sickness". There are numerous modelling studies which have looked at estimating the impact of a variety of strategies on transmission and elimination, however many utilise infection prevalence categories for performing simulations rather than location-specific data. For DRC, modelling studies have made projections at a province-level (i.e. Bandundu), and for health zones (i.e all of Equateur and some in Bandundu),

concluding that there is high heterogeneity in underlying transmission, consequently whether medical-only strategies will suffice to meet elimination of transmission (EOT) by 2030. They find that supplemental, large-scale vector control would be expected to result in rapid EOT across settings. Two highendemicity, village-level studies suggest that regular, high-coverage screening is needed to achieve EOT within 15 years without additional interventions.

Added value of this study

This study presents predictions for EOT across the whole DRC for the first time. Since DRC has the highest disease burden it is critical to understand how far current tools might go towards achieving this 2030 target across the country, and how strategies may need to be adapted for specific locations in the endgame. It also provides a priority list for regions requiring intensified interventions.

Implications of all the available evidence

Our analysis suggests that, whilst many regions of DRC are expected to meet the EOT goal by 2030 with medical-only strategies, for some regions current strategies may need to be bolstered to achieve EOT within the next decade. Although some regions could consider increasing coverage of active screening, vector control appears a desirable supplemental intervention in several specific high-prevalence locations.

1 1. Introduction

The pinnacle of success for an infectious disease programme is to drive to 2 eradication, resulting in complete removal of morbidity and mortality, yet no longer requiring interventions. Of all the human diseases targeted for eradication, only one – smallpox – has currently achieved this objective, yet there are several for which this remains the (potentially illusive) goal (such as 6 polio, Guinea worm, and yaws). Clear lessons that can be learnt from many eradication programmes are: (i) the often slow progress from low to very 8 low case burden, (ii) the ever-increasing effort required per case to tackle 9 remaining infection, and (iii) the question of whether eradication is even 10 epidemiologically or operationally feasible. 11

¹² One step down from eradication is elimination of transmission (EOT) to hu-¹³ mans, acknowledging that transmission pockets could persist in non-human

animal cycles. This goal, arguably, may be almost as challenging and fraught 14 with the same hurdles to overcome as eradication itself. Gambiense human 15 African trypanosomiasis (gHAT, sleeping sickness) is one such disease with 16 the EOT goal and within the last decade it was still known to be extant in 15 17 countries in West and Central Africa¹. This parasitic infection is transmit-18 ted to humans via bites by tsetse, with gHAT symptoms typically increasing 19 in severity over several years and leading to death without treatment. The 20 remarkable progress made to bring down case burden across the continent – 21 falling to below 10,000 cases in 2009 for the first time since the most recent 22 epidemic started in the 1970s, and to only 953 in $2018^{1,2,3}$ – has sparked 23 optimism that EOT may be possible and the World Health Organization has 24 set the goal of EOT by 2030^{4,5}. Indeed gHAT fulfils some of the criteria as-25 sociated with an "eliminable" disease: we have a range of field-proven tools 26 and associated delivery mechanisms as well as means of diagnosis and surveil-27 lance⁶. Unlike smallpox, gHAT is not vaccine-preventable, but wide-spread 28 testing, diagnosis, and treatment have worked well to curtail transmission. 20 The key question is whether current tools for gHAT are sufficient to reach 30 EOT in the next ten years, and if so, how expansive might their use have to 31 be to get there. 32

The Democratic Republic of the Congo (DRC) is the country with the most reported gHAT cases. Due to the concerted efforts of the national sleeping sickness control programme in DRC (PNLTHA-DRC), the number of reported cases dropped below 1,000 in the country in 2018. However, the DRC still accounted for nearly 70% of global cases (660 out of 953 cases) in that year^{1,3}. Therefore, the DRC is the most critical country on which the achievement of EOT by 2030 hinges.

In order to assess EOT feasibility, this study focuses on quantitative fore-40 casting of gHAT across 168 endemic health zones (each have a population of 41 around 100,000 people) in DRC to examine if, how, and when EOT could 42 be expected under strategies based on currently available tools. Previous 43 DRC-specific predictive modelling studies have provided insights into ex-44 pected timelines to EOT in Equateur province⁷, and parts of Bandundu 45 province^{8,9,10,11,12} under continuation of medical-based strategies with or with-46 out vector control. From these studies it is clear that a one-size-fits-all ap-47 proach is unlikely to be sufficient to meet this highly ambitious target in the 48 next decade. Although coverage of active screening has been driven by local 49 numbers of cases, additional data-driven guidance could help to further tailor 50

⁵¹ strategy selection.

In this article, we enlarge the geographical scope of previous predictions to 52 include the whole country, utilising the results of previous fitting¹³ to examine 53 the strategies of active screening (AS) with or without supplemental, large-54 scale vector control (VC) on top of the local passive surveillance (PS) system 55 to stop gHAT transmission by 2030 in DRC. A graphical user interface (GUI, 56 see S2 GUI) to complement this article was set up to provide full model 57 outputs. In this analysis we aim to identify regions which are likely to be 58 successful in achieving local EOT on their current trajectory, and ones where 59 enhanced control may be required to meet this target. Furthermore, we 60 provide a priority list of health zones where intensification of strategies is 61 most urgent based on past intervention coverage and projected timelines to 62 EOT. 63

64 2. Methods

65 2.1. Forward projections

We used a previously developed variant ("Model 4") of the Warwick gHAT model^{8,9,13} to predict gHAT dynamics by considering transmission among 67 humans, tsetse, and non-reservoir animals. This anthroponotic transmis-68 sion model with low-risk and high-risk humans is supported by patterns 69 observed in longitudinal human case data in DRC⁸ and captures systematic 70 non-participation of high-risk groups in the population – anecdotally believed 71 to be working-age people spending time near tsetse habitat, and away from 72 villages during active screening activities. Detailed model illustration and 73 complete mathematical descriptions are available in S1 Model details. 74

The fitted model takes into account previous advances in medical, diagnostic, 75 and control systems; posterior parameters were found by fitting to health-76 zone level data for the period 2000–2016¹³. Major changes include better 77 PS systems in the former province of Bandundu and Bas Congo, improved 78 active case confirmation by video recording of diagnostics in Mosango and 79 Yasa Bonga in Bandundu from 2015, and implementation of large-scale VC 80 in Yasa Bonga since mid-2015. Based on the continuation of the current 81 PS system, we considered four strategies for projections from 2017 to 2050, 82 which included different coverage of AS and whether or not to implement 83 VC from 2020. As summarised in Table 1, AS is assumed be either at the 84 recent (2012–2016) mean level achieved or at the maximum level (maximum 85

achieved during 2000–2016), and hence depend on the historical data in each 86 health zone. Except for Yasa Bonga (which had a reported effectiveness of 87 $90\%^{14}$), a fixed effectiveness of 80% tsetse reduction after one year was used 88 in the strategies with VC. Other tsetse reductions (i.e. 60% and 90%) were 89 examined in sensitivity analyses in S1 Model details. Further model assump-90 tions include: (1) in Yasa Bonga only strategies with VC are considered as it 91 is already in place pre-2017; (2) video confirmation of parasitological diagno-92 sis was launched in 2018 in Bandundu health zones to remove false positives 93 in AS; (3) diagnostic algorithms will be improved to 100% specificity out-94 side Bandundu when the detected case numbers are close to the expected ٩P incidence of false positive detections (see S1 for further details). 96

The data set finished in 2016 and so forward projections were performed 97 from 2017 to 2050, independently for each health zone. Parameter uncer-98 tainty was presented by 1,000 randomly selected sets of parameters from the 90 health-zone-specific posteriors in the fitted model. Observational uncertainty 100 in predicted case numbers each year was considered by drawing ten random 101 samples from the predicted mean dynamics for each set of parameters. In 102 model outputs, 10,000 samples for observable variables such as active and 103 passive cases, and related metrics were generated. On the other hand, unob-104 servable variables like new infections and the year of EOT were predicted by 105 the 1,000 model realisations (parameter uncertainty but no sampling uncer-106 tainty). 107

Table 1: Strategies considered for projections (2017–2050). VC effectiveness is determined by the proportional reduction in tsetse population after one year of implementation. Results of sensitivity analysis on VC effectiveness are available in S1 Model details and S2 GUI. Strategies without VC are not considered in Yasa Bonga because VC has been implemented since the middle of 2015.

Strategy	AS coverage	VC effectiveness	PS coverage
name	from 2017	from 2020	from 2017
MeanAS	Mean (2012–2016)	0%	Samo ag 2016
MaxAS	Max (2000–2016)		
MeanAS+VC	Mean	90% for Yasa Bonga	Same as 2010
MaxAS+VC	Max	80% everywhere else	

108 2.2. Measuring elimination of transmission

As there is no direct way to observe EOT, WHO suggest a primary indicator of zero reported cases to measure the achievement of EOT^{4,15}. However, the number of reported cases depends largely on the strength of medical interventions, so other methods to assess progress towards EOT are desirable to complement imperfect case indicators^{16,17}.

Fortunately, mechanistic modelling provides the means to both infer and 114 predict the unobservable transmission dynamics to assess EOT. Here, we 115 calculated the number of underlying new infections each year in the epidemi-116 ological model. Unlike the discrete nature of populations, the outputs of 117 deterministic models are continuous and whilst they can asymptote to zero 118 they will never reach it. Therefore, to identify a realistic point at which 119 EOT has been achieved, we introduced a proxy threshold (= 1) for annual 120 new infections and assume that EOT is achieved when the number of new 121 infections is below the threshold (see S1 for more details). 122

123 2.3. Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

128 3. Results

¹²⁹ 3.1. Projection trends in different risk settings

Forward projections in 168 health zones are reported in this study; nonendemic health zones, and those with little intervention, and/or case reporting were excluded from the original model fitting and hence from these projections¹³.

Figure 1 shows assumed numbers of people screened and model outputs (i.e. 134 active and passive cases, new infections, and probability of EOT) for the 135 four strategies in two example health zones: Kwamouth (former Bandundu 136 province) and Tandala (former Equateur province). Both health zones had 137 significant numbers of cases in the early 2000s and still have on-going trans-138 mission despite annual AS. Kwamouth, with 1068 reported cases in 2012– 139 2016 (estimated 2015 population of 127,205), falls within WHO's definition 140 of a "high-risk" category for gHAT (1-10 cases/1,000 per year averaged over)141

five years), while Tandala is only "low-risk" (38 reported cases in 2012–2016 142 and estimated 2015 population of 274,945 – i.e. 1–10 cases/100,000 per 143 year). Historical AS data shows that Kwamouth had substantially higher 144 proportions of people screened than Tandala. Despite very high coverage of 145 AS in Kwamouth, achieving EOT by 2030 is predicted to only be possible 146 when VC is added – the model suggests that transmission will be interrupted 147 completely within four years once VC begins. Unlike Kwamouth, Tandala 148 appears extremely likely to achieve EOT by 2030 by MaxAS strategy and 149 EOT even occurs in 60% of projections under the less intensive MeanAS 150 strategy. 151

¹⁵² 3.2. Timelines to, and certainty of, EOT

The year of elimination of transmission (YEOT) is defined as the first year 153 that the EOT criterion (i.e. number of new infections is less than one) is 154 met. Health zone maps of the median YEOT under the four strategies are 155 shown in Figure 2. It is possible for different strategies to have very similar 156 YEOT distributions within a health zone if EOT is expected to have already 157 occurred. Using the value of median YEOT, health zones can be classified 158 into three categories: on track (YEOT ≤ 2030), slightly behind schedule 159 $(2030 < YEOT \le 2040)$, and greatly behind schedule (YEOT > 2040) to met 160 the EOT goal. We predict 74 health zones are on track, 29 are slightly behind 161 the schedule, and 65 are greatly behind schedule under MeanAS strategy. An 162 extra seven health zones are on track while 62 remain greatly behind schedule 163 under MaxAS strategy. Data shows low coverage of AS (defined as lower than 164 25% for mean coverage and 40% for maximum coverage) may be responsible 165 for predicted delays in EOT in health zones outside the former Bandundu 166 province. With VC starting in 2020, all health zones are predicted to achieve 167 EOT by 2024. MaxAS+VC strategy could further bring forward YEOT by 168 up to one year (although the five years data bins in Figure 2 obscure this 169 nuance). 170

The median YEOT provides an average of when to expect EOT but not the certainty that the goal will be met by 2030. The probability of elimination of transmission (PEOT) by 2030, which highly depends on the distribution of YEOT, captures the uncertainty of model predictions. Consequently, low values of median YEOT cannot guarantee EOT by 2030. One example is Inongo in the former Bandundu province, which has a median YEOT of 2019 but the PEOT by 2030 is < 1 under both MeanAS and MaxAS strategies.

Figure 3 shows PEOT by 2030 in each health zone under four strategies. 178 Three uncertainty categories of model predictions are particularly interesting: 179 EOT is very likely to be met by 2030 if PEOT > 0.9, EOT by 2030 is highly 180 uncertain when 0.3 < PEOT < 0.7, and EOT is very unlikely to be met if 181 PEOT < 0.1. The model predicts 42 health zones are very likely to meet 182 the goal and 61 are almost certain to miss it under MeanAS strategy. High 183 uncertainty in EOT is reported in 33 health zones. Despite the distribution 184 of YEOT being shifted forward under MaxAS strategy, only ten extra health 185 zones become very likely to meet the goal by 2030 while 24 health zones 186 remain highly uncertain because of their wide YEOT distributions. With 187 VC starting in 2020, a tight distribution of YEOT means EOT by 2030 is 188 extremely likely everywhere even if its median is quite close to 2030. 189

190 3.3. Prioritising health zones

Decision-making for gHAT strategy is challenging; programmes have the flex-191 ibility to implement nuanced, spatially-heterogeneous interventions, however 192 they must adhere to more general WHO recommendations and budget con-193 straints. In the present study we rank strategies by how ambitious the use 194 of additional interventions is and examine the minimum required to meet 195 the 2030 EOT goal in each health zone – referred to here as the "preferred 196 strategy". The preferred strategy maps under different levels of certainty 197 in EOT as predicted by the model are shown in Figure 4. Under the cri-198 terion of PEOT > 0.9 (left map), preferred strategies are defined as the 199 strategies which achieve EOT by 2030 in at least 90% of simulations. The 200 criterion of PEOT = 1 (right map) further restricts preferred strategies to 201 achieve the goal by 2030 in all simulations. According to the ordered rank-202 ing (MeanAS, MaxAS, MeanAS+VC, and MaxAS+VC), the least ambitious 203 strategy among all that meet the PEOT criterion is selected as the preferred 204 strategy. This order of ambition ranking was based on the following prin-205 ciples: MeanAS represents the continuation of current intervention, MaxAS 206 is the highest level of intervention implemented to date, and VC is a new 207 intervention to all health zones except Yasa Bonga. Notably MaxAS+VC is 208 absent in any of the preferred strategy maps because all health zones are ex-200 pected to achieve the EOT goal by 2030 under MeanAS+VC strategy which 210 requires less resources. Maps showing lower PEOT thresholds (from PEOT 211 = 0.5 upwards) can be found in the GUI (see S2 GUI) and far less intensifi-212 cation would be required if a 50% probability of meeting the goal by 2030 is 213 considered to be sufficient. 214

Switching to intensified strategies is generally expected to increase confidence that EOT will be achieved, although the model predicts very few health zones will eliminate transmission by medical-only strategies with high probability (31% under PEOT > 0.9 and 17% under PEOT = 1). We used the historical data in conjunction with model assumptions to understand the causes of apparent high need for VC and further suggest where and what kind of intensified interventions are needed to achieve EOT by 2030.

Using the WHO's risk categories based on data from 2012–2016, health zone 222 can be classified as: moderate- or high-risk (> 1 case per year on average per)223 10,000, or low- or very low-risk (> 1 but < 100 cases per year on average 224 per 1,000,000). The 125 low- or very low-risk health zones are expected 225 to be on track to meet EOT by 2030. However, the model predicts the 226 majority of them (87 health zones) need VC to achieve EOT by 2030 with 227 more than 95% probability. The apparent discrepancy comes from large 228 uncertainty in model predictions due to limited information arising from low 229 AS coverage. AS provides precious information on quantifying the underlying 230 transmission and affects model predictions. In order to maximise resource 231 efficiency, reductions in AS commonly happen when fewer cases are reported. 232 More than 95% of the low- or very low-risk health zones screened a total of less 233 than 50% of its population in the last five years (i.e. less than 10% annually). 234 As a result, VC is favored in model predictions due to lack of information 235 and may be unnecessary in practice in low- or very low-risk health zones. 236 For moderate- or high-risk health zones, the model predicts nearly all health 237 zones (37 out of 43) need VC to meet EOT by 2030 with more than 95%238 probability. Although VC seems a reasonable tool in moderate- or high-risk 230 health zones, unfortunately it is unlikely to be practical to roll out large-scale 240 VC in all of them in this short timeframe. In health zones outside former 241 Bandundu province that are greatly behind schedule the maximum observed 242 coverage was 40%. When this value was applied as a threshold; Bagata, 243 Bandundu, Bolobo, Kikongo, Kwamouth, and Masi Manimba in the former 244 Bandundu province are on the shortlist of health zones where VC is highly 245 recommended by mathematical modelling. More than 95% of health zones 246 have mean AS coverage lower than 25%, therefore a secondary suggestion is 247 to increase the coverage of AS to at least 25% especially in the moderate- or 248 high-risk health zones. 249



Figure 1: Time series of key model outputs in two example health zones. Kwamouth (left panels) in former Bandundu province and Tandala (right panels) in former Equateur province represent a high-risk and a low-risk health zone, respectively. The top row shows the number of people actively screened, the middle rows show three direct model outputs (active cases, passive cases and underlying new infections from top to bottom), and the bottom row shows the probability of achieving EOT by year. Black lines and box plots indicate data and model fits in the last five years (2012–2016), coloured dashed lines denote the assumed AS starting in 2017, and colour box plots and circles present the predictions for four strategies (as defined in Table 1). Box plots with whiskers showing 95% prediction intervals summarise parameter and observational uncertainty. Full model outputs (2000–2050) of all 168 analysed health zones are available online (see S2 GUI).



Figure 2: Health zone median year of elimination of transmission (YEOT) maps for the DRC. The median YEOT provides the year in which 50% of model simulations reach EOT in each health zone. The top two maps show strategies without VC (except for Yasa Bonga health zone which is shown with VC in all maps) and the bottom maps have VC strategies with 80% vector reduction. The left maps simulate continuation of the mean AS coverage and the right two simulate maximum AS coverage. The uncertainty of YEOT is not shown in these maps (only the average prediction). The exact median values and 95% prediction intervals for YEOT are available online (see S2 GUI).



Figure 3: Health zone probability of elimination of transmission (PEOT) by 2030 maps for the DRC. PEOT reveals the uncertainty of model predictions about whether EOT will occur. Health zones with PEOT > 0.9 (dark blue) will be very likely to achieve EOT by 2030, and PEOT < 0.1 (dark red) will be very unlikely to meet it. Health zones with mid-range PEOT (0.3–0.7) have high uncertainty in the success or failure of the strategy to meet the goal either because (1) the median YEOT is close to 2030, or (2) the wide distribution in the predicted YEOT. The two identical maps (with PEOT = 1 everywhere) at the bottom show that VC is an efficient tool which ensures EOT has extremely high certainty. Maps of PEOT by other years are available online (see S2 GUI).



Figure 4: Health zone preferred strategy maps for EOT by 2030 in the DRC. The preferred strategy is defined as the least ambitious strategy which is predicted to achieve EOT by 2030 with a prescribed confidence level (90%, 95% and 100%). The order of ambition ranking is MeanAS, MaxAS, MeanAS+VC and MaxAS+VC. All health zones are predicted to achieve EOT by 2030 (PEOT = 1) under MeanAS+VC strategy so MaxAS+VC is absent here. MeanAS and MaxAS strategies were not considered in Yasa Bonga because VC started in mid-2015. Preferred strategy maps for smaller PEOT thresholds are available online (see S2 GUI).

250 4. Discussion

The integration of data, model assumptions, and model predictions identifies 251 a priority shortlist of six health zones Bagata, Bandundu, Bolobo, Kikongo, 252 Kwamouth, and Masi Manimba in the former Bandundu province (all of 253 which have maximum AS coverage > 40%) as regions where VC is predicted 254 to be a necessary supplementary tool for eliminating transmission by 2030 255 (see S1 Model details). Other health zones predicted to miss the 2030 EOT 256 goal could also benefit from this tool, although careful consideration is re-257 quired to assess whether scaling up medical interventions is easier to imple-258 ment than introducing large-scale VC. The reported effectiveness of VC is 259 high in general but the variations between locations are non-negligible. Ac-260 cording to our sensitivity analysis on the effectiveness of VC (see S1 Model 261 details), the time difference in achieving EOT could be several years longer 262 with only 60% tsetse reduction, but this is still substantially faster than with 263 medical-only interventions in many settings. Our model forecasting would 264 be more accurate if the location-specific effectiveness of VC was taken into 265 account (which is yet unknown in most health zones). Pessimistic model 266 predictions can be found in some health zones where the coverage of AS is 267 very low recently or historically. Low AS coverage creates additional un-268 certainty in model outputs and therefore can make model predictions overly 269 pessimistic (i.e. they could overstate the need for VC in low- or very low-270 risk health zones). Exploring the minimum AS coverage required to achieve 271 EOT by 2030 would be another mathematical modelling approach to address 272 where and what kind of intensified interventions are needed to achieve EOT. 273

The presented model predictions are based on the model fitted to 2000–2016 274 case data¹³ and assumptions of different strategies starting from 2017. When 275 the new data from 2017 onward becomes available, we will be able to use it 276 to validate our model by changing assumed AS coverage to actual numbers 277 of people screened and then comparing the predicted active and passive cases 278 to reported cases. Subsequent re-fitting to the recent case data would fur-279 ther refine model predictions presented here and is an important step in 280 the continuous process of modelling to support policy (see S1 Model details 281 for details on how this study meets NTD-PRIME principles¹⁸). Our model 282 framework is flexible and could be used to predict the impact of unexpected 283 future changes by estimating how they could alter observable (i.e. reported 284 cases and deaths) and unobservable variables (i.e. new infections); in the 285 present climate of the COVID-19 pandemic and recent Ebola outbreaks in 286

gHAT-endemic parts of DRC, this is particularly relevant and could provide support in planning whether subsequent gHAT interventions should be
altered due to unforeseen interruptions.

The impact of other factors such as the screening of high-risk populations 290 and possible animal reservoirs on gHAT transmission have been studied by 291 mathematical modelling^{8,9,19,20,21,22}. Recruiting high-risk individuals can, un-292 surprisingly, improve the effectiveness of AS and bring down the YEOT sub-293 stantially⁹; the present framework could be extended to quantify the impact 294 of this type of improved AS. Models considering an animal reservoir have 295 largely been inconclusive about the presence of zoonotic transmission (when 296 using longitudinal human case data) however they have indicated that ani-297 mal reservoirs are unlikely to maintain the infection by themselves 8,20 . An 298 analysis including animal reservoirs could yield different results for YEOT 299 predictions presented here, although our previous work suggests that we 300 would probably not expect large qualitative differences. Another concern 301 is asymptomatic humans maintaining transmission 23,24 ; although a few mod-302 elling studies have utilised frameworks explicitly incorporating asymptomatic 303 human infections 21,22,24 , there is limited observational data to parameterise 304 them with high certainty, and it is unclear how their inclusion in this study 305 would impact projections. 306

A new oral drug to treat gHAT, fexinidazole has now been approved for use 307 in DRC, and is being utilised in the country. Despite the obvious advantages 308 for patients, ease of transport and administration, it is not deemed suitable 309 for use in individuals without parasitological case confirmation²⁵, and hence 310 is unlikely to greatly impact on transmission as part of a strategy. A second 311 oral drug, acoziborale, hoped to be a safe single-dose cure, is under clinical 312 trial and could, in principle, radically change the paradigm of diagnostic and 313 treatment algorithms, especially in an AS setting²⁶. The non-toxic compound 314 used in acoziborale may allow mobile screening teams to "overtreat" RDT-315 positive, gHAT suspects without parasitological confirmation. Mathematical 316 modelling could be used to estimate the impact of several potential diagnostic 317 and treatment algorithms and predict the impact of such strategies using 318 acoziborale on EOT before they begin. These types of novel interventions 319 could be particularly helpful as we approach the endgame for gHAT. 320

AS planning by PNLTHA-DRC is guided at a village level by WHO recommendation. This includes stopping AS after three years of zero case de-

tection and then switching to "reactive AS" when new cases arise in PS²⁷. 323 In the present study our four strategies were assumed to carry on indefi-324 nitely without any stopping, however the economic gains and health risks 325 of cessation should be examined. A previous health economic analysis con-326 cluded that VC can be cost-effective at low willingness-to-pay thresholds per 327 disability-adjusted life year averted in high-risk settings²⁸. Taking account of 328 the PNLTHA-DRC algorithm of reactive screening, a novel health economic 329 analysis based on predicted model dynamics would allow for the examination 330 of cost-effective strategies rather than the "preferred strategy" presented here 331 based on a cruder ranking of "ambition". 332

Looking across at other infections targeted for elimination, the enormity 333 of the challenge ahead becomes apparent – with many of these programmes 334 reaching ever lower levels of disease, but failing to meet elimination deadlines. 335 Modelling in this study suggests that, even though elimination of gHAT 336 in the near future may be epidemiologically feasible with current tools, its 337 wide-spread, low-level persistence across the DRC could prove operationally 338 challenging for achievement of the goal in the short-term. In many regions 339 there is considerable uncertainty whether current interventions are sufficient 340 to meet EOT in the next ten years, yet the prospect of intensifying strategies 341 in dozens of health zones may pose a large, or even insurmountable, burden 342 on resources (financial and personnel). As further progress is made towards 343 elimination of gHAT, it will become increasingly crucial to use data-driven 344 methods to optimise the endgame pathway based on practical strategies and 345 use these methods to quantify success. 346

347 Contributors

³⁴⁸ CH, REC, and KSR developed the software and performed the analyses.
³⁴⁹ REC, CH, and PB visualised the results. REC, EMM, and CS analysed the
³⁵⁰ data. KSR developed the methods. CH and KSR wrote the original draft.
³⁵¹ KSR, SEFS, and MJK conceptualised the study. All authors reviewed and
³⁵² approved the final version for publication.

353 Declaration of interests

³⁵⁴ We declare no competing interests.

355

356 Data sharing

³⁵⁷ Data of the Atlas of human African trypanosomiasis can be requested by ³⁵⁸ writing to: Jose Ramon Franco (francoj@who.int) or Gerardo Priotto (pri-

ottog@who.int). Data sharing is subject to WHO data-sharing policies and
data-use agreements with the participating research centres. All model code
is available at Open Science Framework (see S3 Model Code).

362

363 Acknowledgments

The authors thank PNLTHA for original data collection, WHO for data ac-364 cess (in the framework of the WHO HAT Atlas¹⁵), and Cyrus Sinai and Nicole 365 Hoff from UCLA Fielding School of Public Health for providing health zone 366 level shapefiles (current versions can be found at https://data.humdata. 367 org/dataset/drc-health-data). This work was supported by the Bill 368 and Melinda Gates Foundation (www.gatesfoundation.org) through the Hu-369 man African Trypanosomiasis Modelling and Economic Predictions for Pol-370 icy (HAT MEPP) project [OPP1177824] (CH, REC, PB, KSR, and MJK), 371 through the NTD Modelling Consortium [OPP1184344, OPP1156227, and 372 OPP1186851] (KSR, SEFS, and MJK), and through the TRYP-ELIM project 373 [OPP1155293] (EMM and CS) and the Belgian Development Agency (EN-374 ABEL) (EMM and CS). The funders had no role in study design, data col-375 lection and analysis, decision to publish, or preparation of the manuscript. 376

377 Supplementary Information

S1 Model details. Additional information on mathematical modelling
 methodology.

S2 GUI. Results for each health zone level projection can be viewed at:
 https://hatmepp.warwick.ac.uk/projections/v1.

S3 Model Code. The code used to simulate this work is available from:
 https://osf.io/jza27/?view_only=d523cb1edf9c4828bc63cb197e5000b2.

384 References.

 World Health Organization. Global Health Observatory Data Repository. https://www.who.int/gho/neglected_diseases/human_ african_trypanosomiasis/en/ (accessed April 20, 2020).

World Health Organization. WHO report on global surveillance of epidemic-prone infectious diseases. WHO Technical Report 2000. https://www.who.int/csr/resources/publications/ surveillance/WHO_CDS_CSR_ISR_2000_1/en/ (accessed April 20, 2020).

- ³⁹³ 3 Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of
 ³⁹⁴ human African trypanosomiasis at continental and country level: Up³⁹⁵ date to 2018. *PLOS Neglected Tropical Diseases* 2020; 14: e0008261.
- World Health Organization. Report of a WHO meeting on elimination of human African trypanosomiasis (trypanosoma brucei gambiense). WHO Technical Report 2013. https://apps.who.int/iris/ handle/10665/79689 (accessed April 20, 2020).
- Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. The
 journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. *Parasitology* 2014; 141: 748–760.
- Molyneux DH, Hopkins DR, Zagaria N. Disease eradication, elimination and control: the need for accurate and consistent usage. *Trends in Parasitology* 2004; **20**: 347–351.
- Rock K, Pandey A, Ndeffo-Mbah M, Atkins K, Lumbala C, Galvani
 A, Keeling M. Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC. *Epidemics* 2017;
 18: 101–112.
- ⁴¹⁰ 8 Rock KS, Torr SJ, Lumbala C, Keeling MJ. Quantitative evaluation
 ⁴¹¹ of the strategy to eliminate human African trypanosomiasis in the
 ⁴¹² Democratic Republic of Congo. *Parasites & Vectors* 2015; 8: 532.
- 9 Rock KS, Torr SJ, Lumbala C, Keeling MJ. Predicting the impact
 of intervention strategies for sleeping sickness in two high-endemicity
 health zones of the Democratic Republic of Congo. *PLOS Neglected Tropical Diseases* 2017; **11**: e0005162.
- de Vries H, Wagelmans APM, Hasker E, Lumbala C, Lutumba P,
 de Vlas SJ, Klundert Jvd. Forecasting human African trypanosomiasis prevalences from population screening data using continuous time
 models. *PLOS Computational Biology* 2016; **12**: e1005103.

⁴²¹ 11 Davis CN, Rock KS, Mwamba Miaka E, Keeling MJ. Village-scale
⁴²² persistence and elimination of gambiense human African trypanoso⁴²³ miasis. *PLOS Neglected Tropical Diseases* 2019; **13**: e0007838.

- Castaño MS, Aliee M, Mwamba Miaka E, Keeling MJ, Chitnis N,
 Rock KS. Screening strategies for a sustainable endpoint for gambiense sleeping sickness. *The Journal of Infectious Diseases* 2020; pp.
 S539–S545.
- Crump RE, Huang C, Knock E, et al. Quantifying epidemiological drivers of gambiense human African trypanosomiasis across the
 Democratic Republic of Congo. *medRxiv* 2020; https://doi.org/
 10.1101/2020.06.23.20138065 (accessed June 23, 2020).
- Tirados I, Stanton MC, Selby R, et al. Impact of tiny targets on Glossina fuscipes quanzensis, the primary vector of human African trypanosomiasis in the Democratic Republic of the Congo. *bioRxiv*2020; https://doi.org/10.1101/2020.04.07.029587 (accessed April 20, 2020).
- Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of
 human African trypanosomiasis: Update to 2016. *PLOS Neglected Tropical Diseases* 2018; **12**: e0006890.
- Simarro PP, Cecchi G, Franco JR, et al. Monitoring the progress
 towards the elimination of gambiense human African trypanosomiasis. *PLOS Neglected Tropical Diseases* 2015; 9: e0003785.
- ⁴⁴³ 17 NTD Modelling Consortium Discussion Group on Gambiense Human
 ⁴⁴⁴ African Trypanosomiasis. Insights from quantitative and mathemati⁴⁴⁵ cal modelling on the proposed 2030 goal for gambiense human African
 ⁴⁴⁶ trypanosomiasis (gHAT) [version 2; peer review: 2 approved]. *Gates*⁴⁴⁷ Open Research 2020; **3**: 1553.
- Behrend MR, Basáñez MG, Hamley JID, et al. Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling
 Consortium. PLOS Neglected Tropical Diseases 2020; 14: e0008033.
- 451 19 Stone CM Chitnis N. Implications of heterogeneous biting exposure
 452 and animal hosts on Trypanosomiasis brucei gambiense transmission
 453 and control. *PLOS Computational Biology* 2015; **11**: e1004514.

- Mahamat MH, Peka M, Rayaisse Jb, et al. Adding tsetse control to
 medical activities contributes to decreasing transmission of sleeping
 sickness in the Mandoul focus (Chad). *PLOS Neglected Tropical Dis*-*eases* 2017; **11**: e0005792.
- ⁴⁵⁸ 21 Rock KS, Ndeffo-Mbah ML, Castaño S, et al. Assessing strategies
 ⁴⁵⁹ against gambiense sleeping sickness through mathematical modeling.
 ⁴⁶⁰ Clinical Infectious Diseases 2018; 66: S286–S292.
- Castaño MS, Ndeffo-Mbah ML, Rock KS, et al. Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). *PLOS Neglected Tropical Diseases* 2020; 14: e0007976.
- Büscher P, Bart JM, Boelaert M, et al. Do cryptic reservoirs threaten
 gambiense-sleeping sickness elimination? *Trends in Parasitology*2018; 34: 197–207.
- Capewell P, Atkins K, Weir W, et al. Resolving the apparent transmission paradox of African sleeping sickness. *PLOS Biology* 2019; **17**: e3000105.
- World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. WHO Technical *Report* 2019. https://www.who.int/trypanosomiasis_african/
 resources/9789241550567/en/ (accessed April 20, 2020).
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03087955, Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense (OXA002); March 23, 2017 [cited April 20, 2020]; [about 481 4 screens]. Available from: https://www.clinicaltrials.gov/ct2/ show/NCT03087955 (accessed April 20, 2020).
- World Health Organization. Control and surveillance of human
 African trypanosomiasis: report of a WHO expert committee. WHO *Technical Report* 2013. https://apps.who.int/iris/handle/
 10665/95732 (accessed April 20, 2020).

Sutherland CS, Stone CM, Steinmann P, Tanner M, Tediosi F. Seeing
beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense. *The Lancet Global Health* 2017; 5: e69–e79.